Summary
The efficacy and safety of metformin in the treatment of obese, non-insulin-dependent, diabetic subjects poorly controlled by insulin after secondary failure to respond to sulphonylureas has been investigated. Fifty insulin-treated, obese diabetics participated in this prospective, randomised double-blind six-month trial. After a four-week run-in period, during which all patients were given placebo (single-blind), patients were randomly assigned to continue to receive placebo or to active treatment with metformin.
At six months, there was a relevant and significant improvement in glycaemic control in diabetics receiving the combined insulin-metformin treatment (decrease in glucose −4.1 mmol·l−1; glycosylated haemoglobin A1 decrease −1.84%). No significant changes were seen in diabetics receiving insulin and placebo. There was a significant decrease in blood lipids (trygliceride and cholesterol), an increase in HDL-cholesterol and a reduction in blood pressure in diabetics taking metformin. These postive findings were most marked in the 14 diabetics who experienced a good response to metformin (glucose profile <10 mmol·l−1), and were less marked but still significant in the remaining 13 diabetics, whose response to therapy was not so good (glucose profile >10 mmol·l−1). The fasting insulin level was significantly lower after six months of combined insulin-metformin treatment as shown by a 25% reduction in the daily dose of insulin (−21.6 U/day).
Metformin was well tolerated by all diabetics. Combining metforming with insulin in obese, insulin-treated and poorly controlled diabetics may represent a safe strategy to achieve better glycaemic control with a reduction in certain metabolic risk factors associated with the increased incidence of cardiovascular disease in diabetes mellitus.
Similar content being viewed by others
References
Morris RD, Rimm DL, Hartz AJ, Kalkhoff RK, Rimm A (1989) Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32,662 adults white women. Am J Epidemiol 130: 112–120
Wolfenbuttel BHR, Weber RFA, Van Koetsveld PM, Verschoor L (1989) Limitations of diet therapy in patients with non-insulin-dependent diabetes mellitus. Int J Obesity 13: 173–182
Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D (1986) Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 9: 129–133
Laasko M, Sarlund H, Pyorrala K (1986) Prevalence of insulin deficiency among initially non-insulin-dependent middle-aged diabetic individuals. Diabetes Care 9: 228–231
Foley JE, Kashiwagi A, Verso MA, Reaven G, Andrews J (1983) Improvement of in vitro insulin action after one month of insulin therapy in obese non-insulin dependent diabetics. J Clin Invest 72: 1901–1909
Stout RW (1979) Diabetes and atherosclerosis: the role of insulin. Diabetologia 16: 141–150
Scheen AJ, Lefebvre PJ (1989) Insulin versus insulin plus sulfonylureas in type-2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pr 6: S33-S43
Bailey CJ (1988) Metformin revisited: its action and indications for use. Diabetic Med 5: 315–320
Giugliano D, Cozzolino D, Salvatore T, Torella R, Franchimont P, D'Onofrio F, Lefebvre PJ (1988) Altered metabolic and hormonal responses to epinephrine and beta-endorphin in human obesity. J Clin Endocrinol Metab 67: 238–244
Walter E (1980) Biomathematik für Mediziner 2nd ed. Teubner, Stuttgart
Olefsky JM, Kolterman OG (1981) Mechanism of insulin resistance in obesity and non-insulin-dependent (Type II) diabetes Am J Med 70: 151–168
Lebovitz HE (1990) Diabetes mellitus: theory and practice. In: Rifkin H, Porte D Jr (eds) Elsevier, New York, pp 554–574
Reaven GM, Chen YDI, Coulston AM, Greenfield MS, Hollenbeck C, Lardinois GC, Schwartz H (1983) Insulin secretion and action in non-insulin-dependent diabetes mellitus: is insulin resistance secondary to hyperinsulinaemia? Am J Med 75 [Suppl 5B]: 85–93
Bailey TS, Mezitis NHE (1990) Combination therapy with insulin and sulfonylureas for type-II diabetes. Diabetes Care 13: 687–695
Jackson RA, Hawa MI, Jaspan JB, Sim BM, Di Silvio M, Featherbe D (1987) Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 36: 636–640
Swislocki ALM, Hoffman BB, Reaven GM (1989) Insulin resistance, glucose intolerance and hyperinsulinaemia in patients with hypertension. Am J Hypertension 2: 419–423
Natali A, Santoro D, Palombo C, Ghione S, Ferrannini E (1990) Diabetes and high blood pressure. Diabetes Nutr Metab 3: 67–84
Landin K, Tengborn L, Smith U (1991) Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 229: 181–187
Schneider J (1991) Effects of metformin on dyslipoproteinemia in non-insulin-depentend diabetes mellitus. Diabete Metab 17: 185–190
Hulley SB, Roseman RH, Bawol RD, Brand RJ (1980) Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302: 1383–1389
Austin MA (1989) Plasma triglyceride as a risk factor for coronary heart disease: The epidemiological evidence and beyond. Am J Epidemiol 129: 249–259
Castelli WP (1986) The triglyceride issue: a view from Framingham. Am Heart J 112: 432–440
Reaven GM, Chen Y-DI (1988) Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes/Metab Rev 4: 639–652
Zavaroni I, Dell'Aglio E, Bonora E, Alpi O, Passeri M, Reaven GM (1987) Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. Am J Med. 83: 609–612
Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1495–1607
Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham Study. JAMA 241: 2035–2038
Quatraro A, Giugliano D, Minei A, et al. (1990) Incidence of cardiovascular complications in elderly diabetic patients. 2nd International Congress on Hypertension in the Elderly: Focus on Risk Factors. Rome, 90A
Hollenbeck CB, Johnston P, Varasteh BB, Chen Y-DI, Reaven GM (1991) Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabete Metab 5: 483–489
Stout RW (1990) Insulin and atheroma: a 20-yr perspective. Diabetes Care 13: 631–654
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giugliano, D., Quatraro, A., Consoli, G. et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44, 107–112 (1993). https://doi.org/10.1007/BF00315466
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315466